Development of in vitro biopharmaceutics tools for predicting the bioavailability of subcutaneously injected monoclonal antibodies and oligonucleotides

Karin Somby,Valerio Campagna,Manuel V. Sánchez-Félix,Ben Forbes,Driton Vllasaliu
DOI: https://doi.org/10.1080/17425247.2024.2403469
2024-09-23
Expert Opinion on Drug Delivery
Abstract:KEYWORDS: Subcutaneous (SC) injection is a well-established route of administration for drugs that are not deliverable by the oral route [ Citation 1 ]. This includes biopharmaceuticals, the approvals of which by the US Food and Drug Administration in 2022 outpaced those for small-molecule new molecular entities. The potential of this delivery route is underscored by the potential for SC biological therapies across diverse therapeutic areas including diseases within oncology, immunology, neurology and cardiology. Two modalities for which SC injection is emerging as a preferred route are monoclonal antibodies (mAB) [ Citation 2 ] and oligonucleotides.
pharmacology & pharmacy
What problem does this paper attempt to address?